Real-World Study of Post-Resistance Treatment Strategies in Advanced Breast Cancer Following CDK4/6i, PIK3CA Inhibitors, or T-DXd

NCT07073755 · clinicaltrials.gov ↗

RECRUITING

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Breast Cancer
Drug Resistance
Hormone Receptor-Positive Breast Cancer
HER2-positive Breast Cancer
Triple-Negative Breast Cancer (TNBC)
Treatment Decisions

Sponsor

Hunan Cancer Hospital